All In Biotech

Drug Trial Radar · NCT03307785

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Oct 12, 2017

Primary completion

Feb 26, 2020

Study completion Dec 11, 2024

Sponsor

Lead sponsor
Tesaro, Inc.GSK (GSK)
Sponsor type
Industry
First posted
Oct 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study. Part D: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study. Part E: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part F: To test the safety and tolerability of combination therapy with Carboplatin-Pemetrexed, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part G: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part H: To test the safety and tolerability of combination therapy with Carboplatin-nab-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part I: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-022 and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Conditions

  • Neoplasms
  • Metastatic Cancer
  • Advanced Cancer
  • Solid Tumor
  • Non Small Cell Lung Cancer Metastatic
  • Non Small Cell Lung Cancer Stage IIIB
  • Non Small Cell Lung Cancer

Interventions

  • NiraparibDrug

    Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.

  • TSR-042Drug

    TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).

  • Carboplatin-PaclitaxelDrug

    Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer \[NSCLC\], ovarian cancer, endometrial cancer, and head and neck cancer.

  • BevacizumabDrug

    Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.

  • TSR-022Drug

    TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells. TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.

  • Carboplatin-PemetrexedDrug

    Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients

  • Carboplatin-Nab-PaclitaxelDrug

    Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Dose-limiting Toxicity (DLT)Time frame: 21 days
  2. Part B: Number of Participants With DLTTime frame: 21 days
  3. Part C: Number of Participants With DLTTime frame: 21 days
  4. Part D: Number of Participants With DLTTime frame: 21 days
  5. Part E: Number of Participants With DLTTime frame: 21 days
  6. Part F: Number of Participants With DLTTime frame: 21 days
  7. Part G: Number of Participants With DLTTime frame: 21 days
  8. Part H: Number of Participants With DLTTime frame: 21 days
  9. Part I: Number of Participants With DLTTime frame: 21 days
  10. Part A: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs)Time frame: Up to 28.5 months
  11. Part B: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 28.5 months
  12. Part C: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 22.5 months
  13. Part D: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 9.5 months
  14. Part E: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 4.4 months
  15. Part F: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 3.5 months
  16. Part G: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 24 months
  17. Part H: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 24 months
  18. Part I: Number of Participants With Non-serious TEAEs, STEAEs and AESIsTime frame: Up to 24 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Encinitas, California

  • GSK Investigational Site

    San Marcos, California

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    Canton, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.